Quarry LP raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 33.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,000 shares of the company’s stock after purchasing an additional 2,500 shares during the period. Quarry LP’s holdings in BridgeBio Pharma were worth $255,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of the stock. Profund Advisors LLC raised its position in BridgeBio Pharma by 1.1% during the 2nd quarter. Profund Advisors LLC now owns 51,029 shares of the company’s stock worth $1,293,000 after purchasing an additional 555 shares during the last quarter. Bfsg LLC raised its position in BridgeBio Pharma by 175.6% during the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company’s stock worth $31,000 after purchasing an additional 790 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in BridgeBio Pharma by 17.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock worth $135,000 after purchasing an additional 801 shares during the last quarter. Amalgamated Bank raised its position in BridgeBio Pharma by 24.7% during the 2nd quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock worth $123,000 after purchasing an additional 962 shares during the last quarter. Finally, Diversified Trust Co raised its position in shares of BridgeBio Pharma by 3.0% in the 3rd quarter. Diversified Trust Co now owns 36,772 shares of the company’s stock worth $936,000 after acquiring an additional 1,059 shares in the last quarter. 99.85% of the stock is owned by institutional investors.
BridgeBio Pharma Stock Down 1.6 %
Shares of NASDAQ BBIO opened at $26.66 on Friday. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $44.32. The stock’s 50 day moving average price is $25.17 and its 200-day moving average price is $26.12. The company has a market capitalization of $5.04 billion, a PE ratio of -11.06 and a beta of 1.08.
Insider Transactions at BridgeBio Pharma
Analyst Ratings Changes
BBIO has been the subject of several research analyst reports. HC Wainwright lifted their price objective on BridgeBio Pharma from $43.00 to $49.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Scotiabank lifted their price objective on BridgeBio Pharma from $45.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, November 25th. Leerink Partners lowered their price objective on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Oppenheimer initiated coverage on BridgeBio Pharma in a research report on Thursday, October 3rd. They issued a “market perform” rating for the company. Finally, Piper Sandler initiated coverage on BridgeBio Pharma in a research note on Wednesday, September 4th. They issued an “overweight” rating and a $46.00 target price for the company. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $48.43.
Check Out Our Latest Research Report on BBIO
BridgeBio Pharma Profile
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Read More
- Five stocks we like better than BridgeBio Pharma
- 3 Best Fintech Stocks for a Portfolio Boost
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- Why Invest in 5G? How to Invest in 5G Stocks
- BlackRock Makes Waves With $12B Private Credit Acquisition
Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report).
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.